-
The first tests of the anticancer drug PAC-1 in human clinical trials show promise
Time of Update: 2023-02-03
Dudek said the phase I clinical trial is designed to test whether a new drug compound has worrisome side effects or toxicity in human patients.
Dudek said the phase I clinical trial is designed to test whether a new drug compound has worrisome side effects or toxicity in human patients.
-
Cancer breakthrough: Predict within hours whether a cancer patient will survive chemotherapy
Time of Update: 2023-02-01
"Early response evaluation by single cell signaling profiling in acute myeloid leukemia Benedicte Sjo TislevollResearchers at the University of Bergen in Norway have discovered a new method that can predict within hours whether certain cancer patients will survive chemotherapy.
-
Lung cancer becomes chronic? Expert: It takes a lot of people to work together to achieve the goal
Time of Update: 2022-11-25
disease Fang Jian pointed out that with the development of targeted drugs, immunotherapy drugs, and multidisciplinary comprehensive treatment, the overall survival rate of patients has also been improved through precise individualized treatment.
-
Take you to the Japanese proton therapy "guide" hospital and learn about the proton therapy process
Time of Update: 2022-11-25
Non-invasive, painless, patients only need to lie on the bed, receive irradiation, can accurately "blast" tumor cells; Each treatment process does not exceed 30 minutes, after the end of the treatment
-
The second-line treatment of liver cancer has added "fierce general"! The successful approval of the indication for remoxizumab has brought more hope to patients in China
Time of Update: 2022-10-13
The results showed that the study reached the main positive endpoint of OS, and the survival benefit of patients with advanced liver cancer with advanced liver cancer with remoxizumab single-agent second-line treatment AFP≥ 400 ng/ml was significantly higher than placebo 。 Among them, the median OS of patients in the remoxilizumab group was 8.
-
2021CSCO: Current and prospects of precision radiotherapy combined with immunotherapy for lung cancer
Time of Update: 2021-10-10
Progress in radiotherapy combined with immunotherapy for lung cancerProgress in radiotherapy combined with immunotherapy for lung cancerA phase II KEYNOTE-799 study evaluated the safety and efficacy of pembrolizumab combined with concurrent radiotherapy and chemotherapy in the treatment of stage III unresectable NSCLC .
-
Beida Pharmaceuticals BPI-23314 drug clinical trial application accepted
Time of Update: 2021-08-16
On the 29th, Betta Pharmaceuticals announced that it received the "Notice of Acceptance" issued by the NMPA, and the company declared BPI-23314 tablets for the treatment of malignant hematological tumors (including but not limited to myelofibrosis and other myeloproliferative tumors and myelodysplastic syndromes.
-
Clin Cancer Res: Efficacy and safety of ribociclib combined with exemestane + everolimus in the treatment of advanced HR+/HER2- advanced breast cancer with CDK4/6 inhibitors: stage I/II TRINITI-1
Time of Update: 2021-07-31
In summary, the TRINITI-1 study shows that for patients with endocrine resistance HR+/HER2-advanced breast cancer who have progressed after treatment with CDK4/6 inhibitors (CDK4/6i), block CDK4/6 and PI3K/AKT/mTOR pathways It shows anti-tumor efficacy and safety, which is worthy of further exploration .
-
The first class 1 new drug
Time of Update: 2021-07-31
Text | plus oneOn July 24, the CDE official website showed that Qilu Pharmaceutical submitted and accepted a listing application for a new class 1 drug "Yiluok Tablets" .
-
New Drug Development: Anti-HER3 Targeted Therapy 30 Years of Creeping Road
Time of Update: 2021-04-27
The pan-HER family inhibitor Sym013 is a mixture of six humanized full-length monoclonal antibodies against three targets of EGFR, HER2, and HER3, and has been shown to reduce the growth of cancer cells in vivo and in vitro.
-
Nat Cancer: Between brain cancer and tissue repair
Time of Update: 2021-03-11
This suggests that some glioblastomas begin to form during normal tissue healing, a process that produces new cells to replace cells lost to injury, derails due to mutations, and may even disappear many years before the patient develops symptoms.
-
Br J Cancer: Bovine white blood cell extract ICRP induces the occurrence of immunogenic cell death in breast cancer cells and builds long-term anti-tumor memory
Time of Update: 2021-02-24
further studies showing that preventive vaccination of ICRP-KCC can prevent tumor formation in BALB/c mouse models and induce long-term anti-tumor memory, including the maturation of DC in the lymph nodes, the increase of CD8-T cells in the lymph nodes, the area of exosome blood and tumors, and the specific cells of lysotoxic tumors.
-
Science Sub-Journal Reveals: Secret Weapon to Suppress Tumor Recurrence - β Blocker Blocker
Time of Update: 2020-12-22
In a study published December 2 in Translation Scienceal Medicine, researchers at AstraZeneone and the Wistar Institute and others found that the reactivation of tumor cells relied on neutral granulocytes and stress hormones, and that β-blockers prevented tumor cells in mice from reactivation.
-
Radiology: How much breast cancer will be missed without digital mammography
Time of Update: 2020-12-16
as a whole, breast cancers examined with DBT were mostly immersive (P .lt; .001), had fewer positive lymph nodes (P .04) and distant metastasis (P s .01), and had a lower rate of FN incidence of advanced breast cancer (odds ratio, 0.95% CI: 0.5, 1.5).
-
Selection of Peptides for Specific Delivery of Oligonucleotides Into Cancer Cells
Time of Update: 2020-12-15
When one of the selected peptides was conjugated to an antisense oligonucleotide against the ErbB2 receptor, specific delivery to breastcancer cells was demonstrated.
The established biopanning procedure should help in the rational selection of cancer-targeting peptides for specific delivery ofDNA and RNA oligonucleotides into cancer cells.
